Stanford University scientists have implicated a logjam of three long, stringy substances behind deadly thick sputum in COVID-19 patients who need a machine to help them breathe. One of these substances may prove especially amenable to treatment with a drug invented long ago for another purpose. It may also play a role in long COVID.
Antibodies generated by COVID-19 vaccines are more suited to recognizing viral variants than antibodies that arise from natural infection, according to a study by researchers at Stanford Medicine.
Antibodies generated by COVID-19 vaccines are more suited to recognizing viral variants than antibodies that arise from natural infection, according to a study by researchers at Stanford Medicine.
People who have been treated with rituximab, a widely used cancer drug, or similar drugs respond poorly or not at all to subsequent COVID-19 mRNA vaccines, according to a study by researchers at Stanford Medicine.
Blood drawn from patients shortly after they were infected with SARS-CoV-2, the virus that causes COVID-19, may indicate who is most likely to land in the hospital, a study led by Stanford Medicine investigators has found.
The Moderna and Pfizer BioNTech vaccines prevented COVID-19 infection in cancer patients, particularly in those whose treatment concluded more than six months before vaccination, say researchers at Stanford, Harvard and the VA.
The Moderna and Pfizer BioNTech vaccines prevented COVID-19 infection in cancer patients, particularly in those whose treatment concluded more than six months before vaccination, say researchers at Stanford, Harvard and the Va.
Data suggest that between 10% and 30% of those who have had an acute SARS-CoV-2 infection will experience the persistent pattern of symptoms known as long COVID.
A Stanford study at a California prison found that although there were more breakthrough COVID-19 infections than before the emergence of the delta variant, vaccinated prison residents had few symptomatic cases.
The study, which analyzed early vaccine immune response in 2,099 dialysis patients, found that 33% of those vaccinated with Johnson & Johnson did not develop coronavirus antibodies, compared with 4% of those who received the Pfizer-BioNTech vaccine and 2% who received the Moderna vaccine. The study is one of the first to compare immune response … Continued